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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 
(COVID-19) continues to have a devastating impact across the globe. However, little is known 
about the disease course in patients with autoimmune hepatitis (AIH). 
 
Methods  
Data for patients with AIH and SARS-CoV-2 infection were combined from three international 
reporting registries and outcomes were compared to those with chronic liver disease of other 
aetiology (non-AIH CLD) and to patients without liver disease (non-CLD).  
 
Results: 
Between 25th March and 24th October 2020, data were collected for 932 patients with CLD and 
SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). Fifty-eight (83%) of AIH 
patients were taking one or more immunosuppressive drug. There were no differences in rates of 
major outcomes between AIH and non-AIH CLD including hospitalization (76% vs 85%; p= 0.06), 
ICU admission (29% vs. 23%; p=0.240), and death (23% vs. 20%; p=0.643). Factors associated 
with death within the AIH cohort included age (OR 2.16/10 years; 1.07–3.81), Child-Turcotte-Pugh 
(CTP) class B (OR 42.48; 4.40–409.53), and CTP-C cirrhosis (OR 69.30; 2.83–1694.50), but not 
use of immunosuppression. Propensity score matched (PSM) analysis comparing AIH with non-
AIH CLD demonstrated no increased risk adverse outcomes including death (+3.2%; -9.2%–
15.7%). PSM analysis of AIH versus non-CLD patients (n=769) demonstrated increased risk of 
hospitalization with AIH (+18.4%; 5.6–31.2%), but equivalent risk of all other outcomes including 













AIH patients were not at increased risk of adverse outcomes despite immunosuppressive 
treatment compared to other causes of CLD and to matched cases without liver disease.  
 














Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a 
rare chronic inflammatory liver disease. This study combines data from three large registries to 
describe the course of COVID-19 in this patient group. We show that AIH patients do not appear 
to have an increased risk of death from COVID-19 compared to patients with other forms of liver 
disease and compared to patients without liver disease, despite the use of medications which 












• This is the largest cohort of patients with autoimmune hepatitis and laboratory proven 
SARS-COV-2 infection reported to date.  
• There were no differences in rates of major adverse COVID-19 outcomes including 
hospitalization, intensive care unit (ICU) admission, and death between AIH patients and 
those with other aetiologies of liver disease. 
• When compared to patients without liver disease in propensity score matched analysis, 
patients with AIH had higher rates of hospitalization but no increased risk of ICU admission 
or death despite potential reporting of AIH cases with more severe baseline liver disease. 
• Independent risk factors for death in AIH patients were age and baseline liver disease 


























Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and resultant 
coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe 
[1]. Since the onset of the pandemic, the scientific and clinical community have strived to 
understand the contributions of specific disease phenotypes to SARS-COV-2 susceptibility and 
subsequent adverse outcomes [2]. Recently, large international and multicentre cohorts have 
shown baseline liver disease severity and alcohol related liver disease (ALD) to be independently 
associated with COVID-19 mortality, with decompensated cirrhosis representing a particularly 
high-risk group [3-6]. In contrast, several studies have demonstrated no significant increased risk 
of critical COVID-19 in patients with previous liver transplantation despite high rates of 
immunosuppression [7-9]. However, no studies have yet evaluated the disease course and 
outcomes specifically for patients with autoimmune hepatitis (AIH), a large proportion of which will 
be on concurrent immunosuppressive agents.  
 
The clinical impact of pre-existing immunosuppression in COVID-19 remains complex and 
incompletely defined. Observations in inflammatory bowel disease and rheumatological 
conditions have suggested a more severe disease course in those under maintenance treatment 
with thiopurines or corticosteroids, respectively [10, 11]. Furthermore, a multicentre study in Spain 
demonstrated a higher incidence of SARS-CoV-2 in immunosuppressed liver transplant recipients 
compared with the general population [8]. In contrast, dexamethasone now has an established 
role in the management of hospitalised patients with COVID-19 potentially through modification 
of the hyperactive immune response, and has been shown to reduce mortality by a third in 











Current expert recommendations advocate against the routine modification of 
immunosuppressive therapy in patients with AIH both before and after SARS-CoV-2 infection [13, 
14]. However, there is little evidence beyond expert consensus and very small cohorts to support 
these recommendations [15, 16]. Furthermore, given the resurgence of the virus in many areas 
of the world, clinicians and policy makers are being forced to carefully risk stratify patients to 
establish who may benefit most from enhanced physical and social distancing. A detailed 
understanding of the clinical course of COVID-19 in patients with AIH is therefore urgently 
required. 
 
The current study represents an international collaborative effort, bringing together data from 
three large-scale reporting registries: The European Association for Study of the Liver (EASL) 
supported COVID-Hep registry, the American Association for the Study of Liver Diseases 
(AASLD) supported SECURE-cirrhosis registry and the European Reference Network on 
Hepatological Diseases (ERN RARE-LIVER). To our knowledge, we describe the epidemiology, 
presentation, disease course and outcomes of the largest cohort of patients with SARS-CoV-2 
infection and AIH and offer statistical comparisons with liver disease of other aetiologies and to a 











Setting and study design 
We combined the data from three multinational registries for patients with laboratory confirmed 
SARS-CoV-2 and AIH collected between March 25th 2020 and 24th October 2020. These 
registries included the R-LIVER COVID-19 registry (co-ordinated by the European Reference 
Network on Hepatological Diseases [ERN RARE-LIVER], with R-LIVER being the general registry 
of ERN RARE-LIVER), the SECURE-Cirrhosis registry (co-ordinated by University of North 
Carolina, USA, and supported AASLD), and the COVID-Hep.net registry (co-ordinated by 
University of Oxford, UK, and supported by EASL). All three registries were widely advertised 
through the communication channels of multiple endorsing gastroenterology and hepatology 
societies, direct emails to hepatology providers, and through social media. Submitting clinicians 
were asked to complete a case report form of clinical data at the end of their patient’s disease 
course, defined as resolution of clinical signs of COVID-19, discharge from hospital, or death. All 
three registries used an online reporting form which was identical for COVID-Hep and SECURE-
cirrhosis, but different for the R-LIVER COVID-19 registry; copies of both data collection tools are 
available as a Supplementary annex . In order to centralise and amalgamate overlapping report 
form information, case data from the R-LIVER report form was re-entered onto the online COVID-
Hep report form via www.COVID-Hep.net.  
 
Whereas the R-LIVER COVID-19 registry collected data exclusively for autoimmune liver disease 
and other rare liver diseases, COVID-Hep.net and SECURE-Cirrhosis registries also 
simultaneously collected identical data for patients with laboratory confirmed SARS-CoV-2 and 
all other aetiologies of chronic liver disease (CLD). The current study includes 745 cases of CLD 










published analysis from the COVID-Hep/SECURE-cirrhosis registry. However, this prior 
publication did not include any analysis on AIH patients. In addition, two recent publications from 
Italy partially contained descriptive data from 4 patients being included in the registries of this 
study [16, 17]. Contributing centres of ERN RARE-LIVER were asked to report the total number 
of AIH patients of their institution and to report monthly even if no cases of SARS-CoV-2 were 
identified in their AIH patients. 
 
To provide a comparison cohort of patients without CLD, data were also extracted using the 
SECURE-cirrhosis/COVID-Hep data collection tool from electronic patient records of consecutive 
patients testing positive for SARS-CoV-2 over the same time period at Oxford University Hospitals 
NHS Foundation Trust (OUHFT), an organization of four hospitals in and around Oxford in the 
UK, and from the University of North Carolina Hospitals (UNCH). Positive cases from OUHFT and 
UNCH were defined as detection of SARS-CoV-2 by reverse transcriptase polymerase chain 
reaction (RT-PCR) on nasopharyngeal swabs. Any cases of SARS-CoV-2 infection in patients 
with pre-existing chronic liver disease who were identified from the electronic health records whilst 
compiling the non-CLD cohort were subsequently incorporated in the CLD cohort. To minimize 
potential reporting bias, data extraction for the non-CLD cohort was performed by investigators 
blinded to the clinical characteristics and outcomes reported in CLD patients. All data for both 
CLD and non-CLD cohorts were uploaded real-time to the same secure, online, data capture tool. 
All submitted report forms for all cohorts were manually reviewed to assess for data quality, 
completeness and inconsistencies and in some instances, submitting clinicians were contacted 
and asked to provide additional data where appropriate. When combining the R-LIVER COVID-
19 registry and SECURE-Cirrhosis/COVID-Hep datasets, possible dual reporting to both 
registries was identified based on the submitting clinician, centre and matching patient 










Ethical and regulatory approval 
The data collected contained no personal health identifiers and both SECURE-cirrhosis and 
COVID-Hep registries were deemed not to constitute human research by the University of North 
Carolina Office of Human Research Ethics and the University of Oxford Clinical Trials and 
Research Governance (CTRG) respectively. Formal local audit approval was sought and received 
for data acquisition from OUHFT electronic health records (ref: OUH5595). The collection of 
clinical data by R-LIVER was approved by the local ethics committee (ref: PV5548). 
Participants 
All cases of laboratory-confirmed SARS-CoV-2 infection in patients with chronic liver disease 
without prior liver transplantation, aged >16yrs (the age for admission under adult services at 
OUHFT), from any location, and with any symptom profile or disease severity were included in 
the analysis. Cases were excluded if any of the following conditions were met: SARS-CoV-2 
infection was not laboratory-confirmed, the submission was a duplicate, if hospitalization status, 
cirrhosis status, or mortality outcome was not known or not reported, or if the patient was not aged 
16 years or over at the time of SARS-COV-2 positive diagnosis (Fig. 1 ). Patients with variant 
syndromes of PBC and PSC (so-called AIH/PBC or AIH/PSC overlap syndromes) and patients 
with AIH and coexisting liver disease (e.g. AIH with alcohol-related liver disease) were excluded 
from the analysis. This was due to internationally varying diagnostic criteria and difficulty defining 
the predominant liver disease phenotype of variant syndromes from the data capture tools. 
Characteristics and outcomes of patients with variant syndromes and AIH with co-existing liver 
disease are presented in Supplementary table 1 . 
Variables and definitions 
Liver disease stage and aetiology was classified by the reporting clinician. Those with cirrhosis 










class (CTP-A, CTP-B, CTP-C). Throughout this paper the following terminology will be used to 
define the groups; total CLD cohort (CLD), autoimmune hepatitis cohort excluding variant 
syndromes and IgG4-related disease (AIH), CLD without AIH (non-AIH CLD), and patients without 
liver disease (non-CLD). 
Obesity was defined as a body mass index (BMI) of >30 kg/m2; where data on BMI was 
unavailable obesity was assumed to be absent. For analysis of ethnicity, only white ethnicity (as 
the majority classification) as compared to other ethnicities was considered in analysis. For the 
non-CLD cohort, where ethnicity was not recorded, white ethnicity was assumed [18]. A full list of 
ethnicity classifications can be found in the Supplementary annex . 
Statistical methods 
Patient factors and outcome are summarized for all cohorts by occurrence of mortality using 
standard summary statistics (number of events and percentage for binary and median and 
interquartile range for continuous measures). Univariable analysis of mortality by patient 
characteristics was performed using logistic regression. Multivariable comparisons of factors 
associated with death within cohorts were assessed using logistic regression. Only patients with 
data available for each reported data point (with the exceptions of values assumed with regard to 
obesity and ethnicity explained above) were used in multivariable analyses. For sensitivity 
analysis, models were repeated with backwards stepwise selection as described. Fisher’s exact 
test was used to compare proportions between two populations. Exact (Clopper-Pearson) 
binomial confidence intervals were calculated when describing proportions. The absence of 
accurate data on the duration from positive laboratory COVID-19 diagnosis to death in the COVID-
Hep/SECURE cirrhosis registries prevented a time-dependent analysis (e.g. Cox regression and 









To evaluate the effect of the AIH on the COVID-19 disease course we compared major outcomes 
in patients with AIH to both non-AIH CLD and non-CLD cohorts using propensity score 1:2 
matched samples via a nearest neighbour approach (individuals matched according to similar 
propensity score) [19]. Covariables included in the propensity score model were selected based 
on their known associations with severe COVID-19 [2, 20], whilst aiming to provide matched 
variance ratios of between 0.5–2.0 . In AIH versus non-AIH CLD the variables included were age 
in years, interactions with age, sex, and baseline liver disease severity (CLD without cirrhosis, 
CTP-A, CTP-B, CTP-C). Covariables included in the propensity score matched model of AIH 
versus non-CLD were age, interactions with age, sex, hypertension, COPD, heart disease and 
diabetes. Propensity score matched analysis was performed using the teffects function in Stata. 
The average treatment effect on the treated (ATET) was calculated with robust Abadie-Imbens 
standard errors [19]. All statistical analyses were conducted using Stata v15.1 (College Station, 
TX). Similar statistical methods have recently been used to evaluate outcomes in the CLD and 












Chronic liver disease and AIH cohort 
Between 25th March and 24th October 2020 there were a total of 1228 combined case 
submissions to SECURE-cirrhosis/COVID-Hep and R-LIVER COVID-19 registries. After 
exclusions, 932 CLD patients remained (Fig. 1) from 35 countries including 70 with AIH (n=70) 
(Table 1 ). Of note, two paediatric AIH patients were submitted to the registry but were excluded 
from the analysis; one female aged 5-years and one male aged 10-years, both of which had a 
mild disease course and were not hospitalized. A total of 862 non-AIH CLD were included (Table 
2). The major aetiologies within the non-AIH CLD cohort included 362 patients with non-alcoholic 
liver disease (NAFLD; 42%), 233 with alcohol related liver disease (ALD; 27%), 128 with chronic 
hepatitis C virus infection (HCV; 15%) and 121 with chronic hepatitis B virus infection (HBV; 14%). 
The non-AIH CLD cohort also included 19 patients with PSC (2%) and 19 with PBC (2%). Rates 
of major co-morbidities are presented in Table 2;  the number of patients in the CLD cohort with 
unknown BMI who were assumed to be non-obese for the analysis was 116/932 (12%).  
 
Of the AIH patients, major contributory countries included USA 14 (21%), UK 10 (15%), Spain 10 
(15%), Iran 7 (10%), and Italy 7 (10%). Major comorbidities in the AIH cohort included 
hypertension 19 (27%), diabetes mellitus 11 (16%), heart disease 9 (13%), and chronic 
obstructive pulmonary disease (COPD) 3 (4%). Fifty-eight (83%) of AIH patients were taking 
immunosuppression, of which the immunosuppressive agents used were prednis(ol)one 41 
(71%), thiopurines (azathioprine or 6-mercaptopurine) 32 (55%), mycophenolate mofetil (MMF) 9 
(16%), tacrolimus 5 (9%), and budesonide 4 (7%). Thirty AIH patients (52%) were on combined 
immunosuppression with two or more agents. For 19 (27%) AIH patients, information was 










course. In 12 (63%) there were no changes to medications, 5 (26%) azathioprine was 
discontinued, 2 (11%) corticosteroid dosage was reduced, and 3 (16%) corticosteroid dose was 
increased.   
Period prevalence rates of SARS-CoV-2 in AIH patients  
 
In order to report on the unadjusted period prevalence of SARS-CoV-2 infection in the AIH 
population, 19 centres across the ERN RARE-LIVER network in Europe reported the number of 
AIH patients treated per year in addition to the number of cases of AIH testing positive for SARS-
CoV-2. Up until 17th July 2020 SARS-CoV-2 was detected in 20/3043 (0.66%) of AIH patients. A 




Within the same time period as the CLD and AIH cohort, data were collected using an identical 
case report form for 793 consecutive non-CLD patients of which a total of 769 cases remained 
after exclusions (OUHFT 614; UNCH 155) (Supplementary figure 1 ). The non-CLD cohort 
differed significantly from the AIH cohort with regards to age, sex, ethnicity, smoking status, 
baseline serum creatinine and rates of comorbidities including diabetes mellitus, hypertension, 
obesity and renal function (Supplementary table 4 ). The number of patients in the non-CLD 
cohort with unknown BMI who were assumed to be non-obese for the analysis was 158/769 
(20%).  The non-CLD cohort presented here includes 614 patients from OUHFT included in a 










Presenting signs and symptoms 
Data on presenting symptoms was available for 65 (93%) of AIH, 677 (88%) of non-CLD, and 840 
(97%) of non-AIH CLD patients. There were no differences between CLD patients with and 
without AIH in the proportions presenting with respiratory symptoms (74% vs. 77%; p= 0.546), 
gastrointestinal symptoms (26% vs. 22%; p=0.441) and those who were asymptomatic (15% vs. 
16%; p=1.0). Compared to the non-CLD cohort, AIH patients had a higher rate of gastrointestinal 
symptoms at presentation (26% vs 14%; p=0.016), but comparable rates of respiratory symptoms 
(74% vs. 83%; p=0.016), and those who were asymptomatic (15% vs 15%; p=1.0). 
Outcomes 
Hospitalization, intensive care unit admission and death in AIH cohort 
When comparing AIH with non-AIH CLD there were no significant differences in the rates of all 
major outcomes including hospitalization (76% vs 85%; p= 0.060), ICU requirement (33% vs. 
31%; p=0.788), ICU admission (29% vs. 23%; p=0.240), new requirement for renal replacement 
therapy (6% vs. 4%; p=0.522), invasive ventilation (13% vs. 17%; p=0.504) and death (23% vs. 
20%; p=0.643) (Fig. 2A) . The discrepancy between the rates of ICU requirement and ICU 
admission are accounted for by a proportion of severe cases being deemed inappropriate for ICU 
admission or due to lack of ICU availability. Furthermore, rates of mortality did not differ between 
AIH and non-AIH CLD when stratified by baseline CTP class (Fig. 2B). Within the 16 AIH patients 
who died, the major causes of death were COVID-19 lung disease 9 (56%), liver-related 5 (31%) 
and cardiac-related 2 (13%) and these did not differ significantly from those dying in the non-AIH 
CLD cohort. A summary of baseline characteristics and rates of major outcomes in AIH patients 










Characteristics and major outcomes in patients with variant syndromes, 
AILD with co-existing liver disease, PBC, and PSC  
In the cohort of patients with variant syndromes and AIH with co-existing liver disease (n=16) who 
were excluded from the analysis, 14 (88%) received immunosuppressive treatment, 10 (63%) had 
cirrhosis, 12 (75%) were hospitalized, and 4 (25%) died (Supplementary table 1 ). Within the 
cohort of 19 PSC patients, 7 (37%) were on immunosuppressive treatment for inflammatory bowel 
disease (IBD), 9 (52%) had cirrhosis, 13 (57%) were hospitalized, and 4 (17%) died 
(Supplementary table 2 ). The PBC cohort included 19 patients of which 17 (90%) were treated 
with ursodeoxycholic acid (UDCA), 3 (16%) had cirrhosis, 6 (32%) were hospitalized, and 1 
patient (5%) died (Supplementary table 3 ).  
 
Factors associated with mortality within AIH cohort 
Among AIH patients, multivariable analysis of factors associated with death among AIH patients 
demonstrated positive associations with age (OR 2.01 per 10 years; 95% CI 1.07–3.81; p=0.031), 
CTP-B (OR 42.48; 95%CI 4.41–409.53; p=0.001), and CTP-C cirrhosis (OR 69.30; 95%CI 2.83–
1694.50; p=0.009). However, there was no association between the use of immunosuppression 
and mortality. When backwards selection of variables was used with a threshold of p<0.2, the 
same factors remained significantly associated with death (Table 1) . Data included in 
multivariable analysis was available for all patients in all categories.  
 
Associations between AIH and mortality within total CLD cohort  
Among the 932 cases in the total CLD cohort (including 70 patients with AIH), factors associated 
with death in multivariable analysis included age (OR 1.27; 95%CI 1.09–1.50; p=0.003), ALD (OR 










p=0.007), CTP-B (OR 4.79; 95%CI 2.72–8.45; p<0.001), CTP-C (OR 12.41; 95%CI 6.73–22.88; 
p<0.001). When backwards selection of variables was used with a threshold of p<0.2, the same 
factors remained significantly associated with death (Table 2) . Specifically, a diagnosis of AIH 
was not associated with mortality. In addition, when a separate analysis was repeated to include 
only AIH patients who were immunosuppressed as a variable, there remained no significant 
association with death (OR 1.27; 95%CI 0.49–3.34; p=0.623). The total CLD cohort presented 
here includes 745 patients included in a previously published analysis, however this prior analysis 
did not consider AIH as a variable in any logistic regression models [3].   
 
Propensity score matched analysis comparing AIH with non-AIH CLD 
To further assess for an association between an AIH and major outcomes, a propensity score 
matched model was constructed including the variables age, interactions with age, sex, and 
baseline liver disease severity (CLD without cirrhosis, CTP-A, CTP-B, CTP-C) in order to compare 
AIH with non-AIH CLD. Using this model, AIH conferred no additional risk compared with non-
AIH CLD patients across all major outcomes including hospitalization, ICU admission, and death 
(Fig. 3A ). Patient characteristics for the non-AIH CLD cohort after propensity score matching are 
presented in Supplementary figure 6 . 
Propensity score matched analysis comparing AIH with non-CLD cohort. 
A propensity score matched analysis was also performed comparing rates of major outcomes for 
AIH versus the non-CLD cohort derived from OUHFT (UK) and UNCH (USA) during the same 
time period. Variables selected for propensity score matching included age, interactions with age, 
sex, hypertension, COPD, heart disease and diabetes. This demonstrated a significant increased 
risk of hospitalization for AIH patients (+18.4% 95%CI 5.6–31.2%; p=0.005), but no increased risk 














Identifying patient groups at high risk of SARS-CoV-2 infection, or those likely to have a severe 
clinical course of COVID-19 is essential in order to inform treatment decisions and infection 
prevention strategies. Whilst large population studies using electronic health records have 
significantly advanced our understanding of the risks posed by certain comorbidities [2], 
determining the impact of rare conditions on COVID-19 outcomes often requires large-scale 
clinician reporting of individual cases. This work is the first to characterise the disease course 
following SARS-CoV-2 infection in patients with AIH, a subpopulation where outcomes from 
COVID-19 remain poorly defined.  
 
Within our combined registry dataset, multivariable analysis of 70 AIH patients showed that only 
advancing age and baseline decompensated cirrhosis were independent risk factors for death. 
Importantly there was no association between mortality and the use of immunosuppression. 
Furthermore, we detected no association between AIH and death in a multivariable analysis of 
CLD patients, and demonstrated comparable outcomes between AIH and propensity score 
matched cohorts without liver disease, and with CLD of other aetiology. The rates of major 
outcomes and lack of an association between immunosuppression and death in those with AIH 
is consistent with similar findings in the liver transplant population [7, 8]. The reasons for this are 
currently unknown, but presumably local or systemic immunity against SARS-CoV2 infection is 
preserved in spite of immunosuppressive medication. This contrasts with poor outcomes 
observed in patients with advanced liver disease where cirrhosis associated immune dysfunction 











Up until this work, only small case series of patients with AIH and COVID-19 have been published. 
In a report from across several regions in Italy, 10 AIH patients on immunosuppressive treatment 
showed a clinical course of COVID-19 comparable to that of non-immunosuppressed patient [16]. 
Furthermore, telephone-based surveys in Northern Italy did not detect an increased COVID-19 
mortality in patients with AIH [21]. These publications were important early signals for patients 
and their clinicians, but interpretations have been limited by very small sample sizes and 
localisation to one geographical area. This has led to difficulties in formulating clear 
recommendations on the approach to social distancing and use of immunosuppressive 
medication during the pandemic, which has by extension caused significant anxiety and 
uncertainty for patients. Although our data shows that AIH patients are not more susceptible to 
death, many of these patients are currently completely avoiding social contact or “shielding”, 
which may reduce exposure to high SARS-CoV-2 viral load infections associated with worse 
clinical outcomes. It is now critical to vaccinate these patients against SARS-CoV-2 infection, and 
to monitor their response to immunisation which may be attenuated by immunosuppressive 
therapy.  
 
Of note, we did observe greater rates of hospitalisation in AIH patients compared to a matched 
cohort without liver disease. This may relate to AIH patients being generally more likely to be 
hospitalized compared to patients without liver disease and therefore subject to higher rates of 
routine inpatient SARS-CoV-2 testing. In addition, it may reflect a background level of patient and 
clinician anxiety regarding the uncertain impact of immunosuppression on the COVID-19 disease 
course leading to a lower threshold for hospital admission. These anxieties can also be inferred 
from the fact that azathioprine maintenance therapy was discontinued in 25% of AIH patients 










secondary impact of these medication changes on liver disease activity, including the rates of AIH 
flares.  
 
The strengths of the current study include the international nature of case submissions which 
gives a truly global perspective on the impact of SARS-CoV-2 infection in patients with AIH. 
Clinician reporting also minimises the risk of misclassification although we accept that centralised 
diagnostic criteria for cirrhosis are lacking and that assessment of Childs-Turcotte-Pugh class 
includes subjective components. An additional strength is the comparison of AIH cases with a 
matched group of contemporaneous patients without liver disease from the UK and USA (the two 
largest contributors of AIH cases), which strengthens the argument that these patients are not at 
higher risk of adverse COVID-19 outcomes. However, our findings must be interpreted in the 
context of the study’s potential limitations. Despite being the largest collection of AIH patients with 
SARS-CoV-2 to date, the total numbers remain relatively small thus constraining the number of 
variables included in propensity score matching and limiting interpretations with respect to 
variables associated with death within the AIH cohort. Secondly, registry data is vulnerable to 
reporting bias, leading to over-representation of patients with more severe liver disease and more 
severe COVID-19, and it is noteworthy that a majority of case submissions were derived from 
tertiary care centres (Supplementary tables 7 and 8 ). The high rates of cirrhosis in AIH patients 
(54%) found in the current study may be an indication of this reporting bias given that previous 
studies have described a cirrhosis rate of 20-30% in those with AIH [22, 23]. However, despite 
the inclusion of patients with more severe baseline liver disease, we were still unable to identify 
an increased risk of severe COVID-19 and death in the AIH cohort suggesting that the true risk is 
likely to be even lower than reported here. It is also notable that despite the study having 
international reach, the AIH cohort is predominantly derived from western populations which may 
limit external generalisability of the results to other geographical areas. Similarly, the classification 










requirement for ICU are likely to vary between international institutions. Lastly, although a time-
dependent analysis (e.g. Cox regression and Kaplan-Meier curves) may have been preferable 
over logistic regression in evaluating mortality, this approach was not possible due to the lack of 
accurate data on the duration from positive laboratory COVID-19 diagnosis to death in the COVID-
Hep/SECURE cirrhosis registries.  
 
In summary, this study involving more than 1700 patients, helps characterize the COVID-19 
disease course and risk of adverse outcome in 70 patients with AIH. Through multiple 
comparisons with non-AIH CLD and non-CLD cohorts, we demonstrate that AIH does not confer 
major additional susceptibility to adverse outcomes following SARS-COV-2 infection despite the 
potential reporting of cases with more severe liver disease. In this patient group, age and baseline 
liver disease severity remain the most important determinants of outcome in contrast to the use 
of immunosuppression were no negative impact was detected. This should provide some 
reassurance to patients and clinicians and lends weight to recommendations that 
immunosuppressive medication should not routinely be modified or discontinued during the 











The authors thank EASL and ESPGHAN for supporting ERN RARE-LIVER in their efforts for the 
care of patients with rare liver diseases, and to the European Commission and the Free and 
Hanseatic State of Hamburg for financial support for the ERN RARE-LIVER. EB acknowledges 
the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views 
expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, 
or the Department of Health. 
 
COVID-Hep and SECURE-Cirrhosis would like to thank EASL and AASLD respectively for their 
formal support of the registries. COVID-Hep and SECURE-Cirrhosis also thank all the following 
endorsing societies: United European Gastroenterology, British Association for Study of the Liver, 
International Liver Cancer Association, British Society of Gastroenterology, Gastroenterological 
Society of Australia, British Liver Trust, European Liver Patients’ Association, Hellenic Association 
of the Study of the Liver, Hepatology Society of the Philippines. Chinese Portal Hypertension 
Diagnosis and Monitoring Study Group.  
 
Data availability statement 












Author names in bold designate shared co-first auth orship. 
 
[1] COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns 
Hopkins University (JHU). Https://coronavirus.jhu.edu/map.html. 
[2] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bat es C, Morton CE, et al. Factors 
associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-436. 
[3] Marjot T, Moon AM , Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following 
SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. Journal of 
Hepatology 2020. 
[4] Bajaj JS, Garcia-Tsao G, Biggins S, Kamath PS, Wong F, McGeorge S, et al. Comparison of 
mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and 
COVID-19 alone: multicentre matched cohort. Gut 2020:gutjnl-2020-322118. 
[5] Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of 30-day 
mortality in patients with cirrhosis and COVID-19. J Hepatol 2020;73:1063-1071. 
[6] Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, et al. Predictors of Outcomes of COVID-19 
in Patients with Chronic Liver Disease: US Multi-center Study. Clinical Gastroenterology and Hepatology 
2020. 
[7] Webb GJ, Marjot T , Cook JA, Aloman C, Armstrong MJ, Brenner EJ, et al. Outcomes following 
SARS-CoV-2 infection in liver transplant recipients: an international registry study. The lancet 
Gastroenterology & hepatology 2020. 
[8] Colmenero J, Rodríguez-Perálvarez M , Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, et 
al. Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients. Journal of 
hepatology 2020. 
[9] Ravanan R, Callaghan CJ , Mumford L, Ushiro-Lumb I, Thorburn D, Casey J, et al. SARS‐CoV‐2 
infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort 
study. American Journal of Transplantation 2020:ajt.16247-ajt.16247. 
[10] Ungaro RC, Brenner EJ , Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Effect of IBD 
medications on COVID-19 outcomes: results from an international registry. Gut 2020. 
[11] Gianfrancesco M, Hyrich KL , Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics 
associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 
Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020;79:859-866. 
[12] Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in 
Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med 2020. 
[13] Boettler T, Marjot T , Newsome PN, Mondelli MU, Maticic M, Cordero E, et al. Impact of COVID-
19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. 










[14] Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical Best Practice 
Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert 
Panel Consensus Statement. Hepatology (Baltimore, Md) 2020;72:287-304. 
[15] Lleo A, Invernizzi P, Lohse AW, Aghemo A, Carbone M. Management of patients with autoimmune 
liver disease during COVID-19 pandemic. Journal of Hepatology 2020:S0168-8278(0120)30212-30219. 
[16] Gerussi A, Rigamonti C, Elia C, Cazzagon N, Floreani A, Pozzi R, et al. Coronavirus Disease 2019 
(COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. Hepatol Commun 2020. 
[17] Rigamonti C, Cittone MG, De Benedittis C, Rizzi E, Casciaro GF, Bellan M, et al. Rates of 
Symptomatic SARS-CoV-2 Infection in Patients With Autoimmune Liver Diseases in Northern Italy: A 
Telemedicine Study. Clin Gastroenterol Hepatol 2020;18:2369-2371 e2361. 
[18] Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction 
algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ (Online) 2017. 
[19] Garrido MM, Kelley AS, Paris J, Roza K, Meier DE, Morrison RS, et al. Methods for constructing 
and assessing propensity scores. Health services research 2014;49:1701-1720. 
[20] Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects 
in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91-
95. 
[21] Di Giorgio A, Nicastro E, Speziani C, De Giorgio M, Pasulo L, Magro B, et al. Health status of 
patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy. J Hepatol 
2020;73:702-705. 
[22] Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the 
initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 
2008;43:1232-1240. 
[23] Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, 
















Table 1 . Patient characteristics of AIH patients with laboratory-confirmed SARS-CoV-2 infection. Univariable associations with death and associated 
p values assessed by logistic regression. Multivariable analysis for association with death performed using logistic regression including all variables 
apart from laboratory values which form part of the Child-Turcotte-Pugh classification. CI = confidence interval; IQR = interquartile range; CLD, 






Died   
(n=16) 
Univariable analysis  Multivariable analysis  Stepwise selection  
  
Median or n 
(IQR/%) 
Median or n 
(IQR/%) 
Median or n 
(IQR/%) 
Odds Ratio  
(95% CI) p-value 
Odds Ratio  
(95% CI) p-value 
Odds Ratio  
(95% CI) p-value 
Demographics               
Age (per 10-years) 55 (44-71) 55 (38-68) 57 (47-75) 1.18 (0.86–1.63) 0.298 2.01 (1.07–3.81) 0.031 1.75 (1.10 – 2.80) 0.018 
Sex (male) 21 (30%) 17 (31%) 4 (25%) 0.73 (0.20-2.58) 0.620 0.35 (0.06–2.16) 0.257 0.33 (0.06–1.80) 0.199 
Ethnicity (white) 33 (47%) 24 (44%) 9 (56%) 1.61 (0.52–4.95) 0.408 0.83 (0.19–3.73) 0.813    
                
Liver disease severity               
CLD without cirrhosis 32 (46%) 29 (54%) 3 (19%) 1.00 (REF)   1.00 (REF)   1.00 (REF)   
CTP-A 17 (24%) 15 (28%) 2 (13%) 1.29 (0.19–8.57) 0.793 2.91 (0.23–37.51) 0.412 3.14 (0.36–27.46) 0.301 
CTP-B 13 (19%) 6 (11%) 7 (44%) 11.28 (2.25–56.59) 0.003 42.48 (4.41–409.53) 0.001 32.93 (4.20–258.07) 0.001 
CTP-C 8 (11%) 4 (7%) 4 (25%) 9.67 (1.56–60.01) 0.015 69.30 (2.83–1694.50) 0.009 62.00 (4.68–821.987) 0.002 
                
Co-factors               
Any immunosuppression 58 (83%) 47 (87%) 11 (69%) 0.33 (0.09–1.23) 0.098 0.79 (0.10–6.25) 0.822    
Heart disease 9 (13%) 6 (11%) 3 (19%) 1.85 (0.41–8.40) 0.428 0.90 (0.09–8.51) 0.925    
Diabetes mellitus 11 (16%) 10 (19%) 1 (6%) 0.29 (0.03–2.49) 0.261 0.22 (0.01–5.03) 0.344 0.13 (0.01–2.76) 0.191 
COPD 3 (4%) 2 (4%) 1 (6%) 1.73 (0.15–20.46) 0.662 0.93 (0.04–21.03) 0.966    
Hypertension 19 (27%) 15 (28%) 4 (25%) 0.87 (0.24–3.11) 0.826 0.35 (0.04–2.77) 0.317     
          
Baseline laboratory values          
Bilirubin (mg/dL)  1.0 (0.6-2.1) 0.7(0.6-1.5) 2.1 (1.2-3.7) 1.12 (0.95–1.34) 0.175     
Serum albumin (g/dL) 3.8 (3.0-4.2) 4.0 (3.4-4.2) 3.2 (2.7-3.6) 0.86 (0.77–0.96) 0.009     
















(n=742) Died (n=190) 
Univariable analysis  Multivariable analysis  Stepwise selection  
  
Median or n 
(IQR/%) 
Median or n 
(IQR/%) 
Median or n 
(IQR/%) 
Odds ratio  
(95% CI) p value 
Odds ratio  
(95% CI) p value 
Odds ratio  
(95% CI) p value 
Demographics          
Age (per 10-years) 59 (48-68) 57 (46-67) 63 (53-73) 1.03 (1.02–1.04) <0.001 1.27 (1.09–1.50) 0.003 1.30 (1.12–1.52) 0.001 
Sex (male) 583 (67%) 463 (62%) 120 (63%) 1.03 (0.74–1.44) 0.847 0.77 (0.51–1.17) 0.221   
Ethnicity (white) 442 (47%) 320 (43%) 122 (64%) 2.37 (1.70–3.29) <0.001 1.37 (0.92–2.04) 0.124 1.34 (0.91–1.99) 0.137 
               
Liver disease severity              
CLD without cirrhosis 423 (45%) 394 (53%) 29 (15%) 1.00 (REF)   1.00 (REF)     
CTP-A 231 (25%) 188 (25%) 43 (23%) 0.86 (0.59–1.26) 0.441 2.18 (1.24–3.84) 0.007 2.21 (1.29–3.78) 0.004 
CTP-B 163 (18%) 105 (14%) 58 (31%) 2.67 (1.84–3.86) <0.001 4.79 (2.72–8.45) <0.001 5.04 (2.92–8.73) <0.001 
CTP-C 115 (12%) 55 (7%) 60 (32%) 5.77 (3.82–8.70) <0.001 12.41 (6.73–22.88) <0.001 12.43 (6.89–22.43) <0.001 
               
Aetiology             
AIH 70 (8%) 54 (7%) 16 (8%) 1.17 (0.65–2.09) 0.594 1.87 (0.81–4.34) 0.145 1.87 (0.89–3.90) 0.097 
NAFLD 362 (39%) 308 (42%) 54 (28%) 0.56 (0.40–0.79) 0.001 0.98 (0.56–1.71) 0.946   
ALD 233 (25%) 150 (20%) 83 (44%) 3.06 (2.18–4.29) <0.001 1.79 (1.06–3.01) 0.029 1.66 (1.09–2.55) 0.018 
HCV 128 (14%) 98 (13%) 30 (16%) 1.23 (0.79–1.92) 0.357 1.05 (0.59–1.88) 0.87   
HBV 121 (13%) 108 (15%) 13 (7%) 0.43 (0.24–0.78) 0.006 0.96 (0.45–2.07) 0.925   
               
Co-factors              
Smoker 67 (7%) 55 (7%) 12 (6%) 0.84 (0.44–1.61) 0.602 0.53 (0.25–1.14) 0.106 0.51 (0.24–1.09) 0.081 
Obesity 248 (27%) 197 (27%) 51 (27%) 1.02 (0.71–1.45) 0.935 1.07 (0.69–1.65) 0.767   
Heart disease 165 (18%) 114 (15%) 51 (27%) 2.02 (1.39–2.95) <0.001 1.41 (0.88–2.26) 0.151 1.52 (0.96–2.40) 0.071 
Diabetes 339 (36%) 261 (35%) 78 (41%) 1.28 (0.93–1.78) 0.133 1.17 (0.77–1.78) 0.469   
Hypertension 362 (39%) 275 (37%) 87 (46%) 1.43 (1.04–1.98) 0.028 1.05 (0.70–1.59 0.805   
COPD 88 (9%) 64 (9%) 24 (13%) 1.53 (0.93–2.52) 0.094 0.63 (0.3–1.29) 0.204 0.61 (0.30–1.24) 0.179 
non-HCC cancer 113 (12%) 84 (11%) 29 (15%) 1.41 (0.89–2.23) 0.139 1.02 (0.48–2.16) 0.961   
HCC 69 (7%) 51 (7%) 18 (10%) 1.42 (0.89–2.23) 0.224 1.11 (0.57–2.15) 0.761   
          
Baseline Laboratory values          
Creatinine (mg/dL) 0.87 (0.7-1.1) 0.86 (0.7-1.0) 0.92 (0.7-1.2) 1.19 (1.04–1.37) 0.012 1.10 (0.94–1.30) 0.237   
Bilirubin (mg/dL) 0.9 (0.5-1.7) 0.8 (0.5-1.3) 1.4 (0.8–3.3) 1.13 (1.08–1.18) <0.001     
Serum albumin (g/dL) 3.7 (3.0-4.2) 3.8 (3.3-4.2) 3.1 (2.6-3.5) 0.90 (0.88–0.92) <0.001     










Table 2 . Patient characteristics of CLD cohort with laboratory-confirmed SARS-CoV-2 infection including 70 patients with AIH. Univariable 
associations with death and associated p values assessed by logistic regression. Multivariable analysis for association with death was performed 
using logistic regression including all variables apart from bilirubin, albumin, and prothrombin time which form part of the Child-Turcotte-Pugh 
classification. Multivariable analysis demonstrated no associations between a diagnosis of AIH and death. Data was available for all patients in all 
categories (after applying the relevant assumptions for obesity and ethnicity) apart from missing data for creatinine In 70 (8%) bilirubin in 79 (8%), 
albumin 89 (10%), and prothrombin time 202 (22%). The absence or presence of AIH, NAFLD, ALD, HBV, or HCV was determined according to 
that reported by submitting clinician; a minority of patients had combinations of more than one liver disease aetiology except for variant syndromes 
of AIH which were excluded from the analysis. Patients who were reported by the submitting clinician to have a combination of liver disease aetiology, 
were classed as having more than one of NAFLD, ALD, HBV, or HCV in the analysis. CI = confidence interval; IQR = interquartile range; CTP = 
Child-Turcotte-Pugh; AIH = autoimmune hepatitis, NAFLD = non-alcoholic fatty liver disease; ALD = alcohol related liver disease; HBV = chronic 



















Fig. 1 . Total combined submissions of patients with CLD and SARS-CoV-2 infection COVID-Hep/SECURE-
Cirrhosis, and R-LIVER registries between 25th March and 24th October 2020 and the number included in 











Figure 2 . Rates of major outcomes in AIH patients compared to other aetiologies of CLD and mortality between cohorts according to 





Fig. 2A.  Rates of major outcomes following SARS-COV-2 infection in AIH patients compared to patients with non-AIH CLD. The discrepancy 
between the rates of ICU requirement and ICU admission are accounted for by a proportion of severe cases being deemed inappropriate for ICU 
admission or due to lack of ICU availability. Fig. 2B . Comparison of mortality rates following SARS-COV-2 infection between AIH versus non-AIH 
CLD separated by baseline liver disease severity: CLD without cirrhosis (9% vs 7%; p=0.473), CTP-A (12% vs. 19%; p=0.746), CTP-B (54% vs 
34%; p=0.225) CTP-C (50% vs. 52%; p=1.0).   ICU = intensive care unit, RRT = new requirement for renal replacement therapy, CTP = Child-
















Fig 3A.  Plot shows propensity-score matched analyses for major outcomes following SARS-CoV-2 infection for AIH compared to non-AIH CLD. 
Variables selected for propensity score matching were age in years, interactions with age, sex, and baseline liver disease severity (CLD without 
cirrhosis, CTP-A, CTP-B, CTP-C). Bars represent confidence intervals at 95%. The risk of each major outcome between AIH versus non-AIH CLD 
was hospitalization -9.7% (95%CI -20.3%–0.7%; p=0.067), ICU requirement +6.2% (95%CI -0.07%–19.2%; p=0.349), ICU admission +6.6% (95%CI 
-5.6%–18.8%; p=0.289), invasive ventilation -2.9% (95%CI -13.3%–7.6%; p=0.59, and death (+3.2%; 95%CI -9.2%–15.7%; p=0.609). Fig 3B. Plot 
shows propensity-score matched analyses for major outcomes following SARS-CoV-2 infection for AIH compared to the non-CLD cohort. Variables 
selected for propensity score matching were age, interactions with age, sex, hypertension, COPD, heart disease and diabetes. The risk of each 
major outcome between AIH versus non-CLD was hospitalization +18.4% (95%CI 5.6–31.2%; p=0.005), ICU requirement +6.2% (95%CI -6.8%–
19.3%; p=0.349), ICU admission +6.6% (95%CI -5.6%–18.8%; p=0.289), invasive ventilation -2.9% (95%CI -13.3%–7.5%; p=0.590), and death 
+3.2% (95%CI -9.1%-15.6%; p=0.609).  
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